A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention
Conditions
Interventions
- DRUG: Rho-Kinase Inhibitor (AR-12286)
Sponsor
New York Glaucoma Research Institute